We are a profitable and growing company focused on the acquisition, development and commercialization of branded prescription products for specialty physician market segments. Since our inception in 1999, we have successfully funded the acquisition and development of our product portfolio with limited external investment, and have been profitable since 2004. We believe we have significant growth opportunities with our existing product portfolio and we continue to identify and pursue other promising product candidates. Source
No articles found.
DLH (NASDAQ:DLHC) serves federal government clients throughout the United States a...
DLH (NASDAQ:DLHC) serves federal government cli...
Lonza is an integrated solutions provider that creates value along the Healthcare ...
Lonza is an integrated solutions provider that ...
DermTech is the global leader in molecular dermatology, bringing precision medicin...
DermTech is the global leader in molecular derm...
Stoke is pioneering a new way to treat the underlying cause of severe genetic dise...
Stoke is pioneering a new way to treat the unde...
We are a clinical-stage biopharmaceutical company focused on significantly improvi...
We are a clinical-stage biopharmaceutical compa...
Global Blood Therapeutics, Inc. (GBT) is a clinical-stage biopharmaceutical dedica...
Global Blood Therapeutics, Inc. (GBT) is a clin...
Continuing the success of our prior three acquisition vehicles, our latest vehicle...
Continuing the success of our prior three acqui...
Join the National Investor Network and get the latest information with your interests in mind.